Orit Markowitz
Dermatology · New York, NYNPI 1215121538
Payments from drug & device makers
Across 850 payments — averaging $4400.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.2M
- Regeneron$887K
- Amgen$646K
- Janssen Research & Development, LLC$231K
- Sanofi US Services Inc.$182K
- Incyte Corporation$149K
- plus $495K from 28 others
Across 36 payments — averaging $8347.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$93K
- E.r. Squibb & Sons, L.L.C.$88K
- Bausch Health US, LLC$72K
- Sanofi US Services Inc.$42K
- Eli Lilly$5K
- Biofrontera Inc.$63
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $1,150,943 |
| Regeneron | 502 | $887,432 |
| Amgen | 16 | $646,346 |
| Janssen Research & Development, LLC | 100 | $230,607 |
| Sanofi US Services Inc. | 15 | $181,595 |
| Incyte Corporation | 62 | $148,598 |
| E.r. Squibb & Sons, L.L.C. | 9 | $120,175 |
| Eli Lilly | 5 | $108,468 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $98,168 |
| Pfizer | 24 | $76,402 |
| Argenx US, Inc. | 5 | $19,946 |
| Biofrontera Bioscience GmbH | 1 | $18,960 |
| Galderma Laboratories, L.p. | 22 | $18,043 |
| Biofrontera Inc. | 2 | $14,463 |
| Sun Pharmaceutical Industries Inc. | 10 | $10,351 |
| LEO Pharma Inc. | 6 | $7,884 |
| Sanofi | 3 | $864 |
| Johnson & Johnson | 10 | $270 |
| Journey Medical Corporation | 3 | $163 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $130 |
| Almirall LLC | 4 | $113 |
| Genentech USA, Inc. | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. | 3 | $88 |
| EPI Health, LLC | 4 | $62 |
| UCB, Inc. | 2 | $57 |
| Dermavant Sciences, Inc. | 2 | $55 |
| Organon | 2 | $51 |
| Botanix SB Inc | 1 | $31 |
| Merz North America, Inc. | 1 | $26 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $25 |
| Arcutis Biotherapeutics, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Sebela Pharmaceuticals Inc. | 1 | $13 |
How this compares
$3,740,502 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in New York
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- Neil SadickNew York$4.2M
- Alexandra GolantNew York$3.6M
- George HanNew York$3.4M
- David CohenNew York$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.